CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Propranolol Oral Tablet +1 moredrug
Likely dose
Propranolol Oral Tablet 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03049306
NCT03049306Phase 2Completed
CompareCT.gov

Propranolol for Sleep Apnea Therapy

Johns Hopkins University·interventional·Posted Feb 10, 2017·Updated Sep 5, 2024

In Brief

A Phase 2 clinical trial evaluating Propranolol Oral Tablet and Placebo Oral Tablet for Obstructive Sleep Apnea. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The primary objective of this study is to test whether a beta blocker, propranolol, lowers the overnight heart rate sleep in obstructive sleep apnea (OSA) during CPAP withdrawal. The secondary objectives are to test whether propranolol influences sleep architecture, morning blood pressure, and vascular function including reactive hyperemia index (RHI) and a marker of arterial stiffness, augmentation index (AIX).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 10, 2017
Enrollment StartFeb 15, 2017
Primary CompletionMay 1, 2024
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 9.4 years ago

Interventions

Propranolol Oral Tabletdrug

Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)

Placebo Oral Tabletdrug

Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)